Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands

X
Trial Profile

Multicenter Randomized CLinical trial of Endovascular treatment for Acute ischemic stroke in the Netherlands

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alteplase (Primary) ; Alteplase (Primary) ; Urokinase (Primary)
  • Indications Embolism and thrombosis; Haemorrhage; Stroke
  • Focus Therapeutic Use
  • Acronyms MR CLEAN
  • Most Recent Events

    • 11 Jan 2022 Results of MR CLEAN Registry Substudy assessing clinical and safety outcomes of patients with acute ischemic stroke (AIS) and active cancer after endovascular treatment published in the Neurology
    • 14 Oct 2021 Results assessing whether endovascular therapy plus usual care is cost-effective in comparison to usual care alone in acute ischemic stroke patients, published in the Stroke.
    • 20 Sep 2021 Results (n=1161) evaluating the associations of systolic BP in the first 6 hours following EVT with functional outcome and the occurrence of symptomatic intracranial hemorrhage, published in the Stroke

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top